Hims & Hers Health, Inc. Class A Common Stock (HIMS)
27.93
-0.75 (-2.60%)
NYSE· Last Trade: Sep 3rd, 1:42 PM EDT
Detailed Quote
Previous Close
28.68
Open
28.88
Bid
27.91
Ask
27.92
Day's Range
27.71 - 29.12
52 Week Range
13.74 - 65.30
Volume
7,004,056
Market Cap
5.36B
PE Ratio (TTM)
54.77
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
12,406,191
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
The DJS Law Group reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) (NYSE: HIMS) on behalf of those who purchased or acquired HIMS securities between August 4, 2025 and July 29, 2026, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.). Investors have until November 2, 2026, to file for lead plaintiff status.
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company’s securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) between August 4, 2025 and July 29, 2026, inclusive.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”).
Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026. Hims describes itself as a company that “operates a health and wellness platform that connects consumers to licensed healthcare professionals.”
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) common stock between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). Hims & Hers Health, Inc. investors have until November 2, 2026 to file a lead plaintiff motion.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NASDAQ: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313, on behalf of persons and entities that purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, marking the first Eucalyptus brand to transition to the Hims brand.
PHILADELPHIA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers” or the “Company”) for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made subscription cancellations unnecessarily difficult.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Hims & Hers Health (NYSE:HIMS...
Check out the companies making headlines yesterday: Funko (NASDAQ:FNKO): Pop culture collectibles manufacturer Funko (NASDAQ:FNKO) rose by 4.9% on Monday aft...
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 9.2% in the afternoon session after Bloomberg reported that Visa enrolled the...
Visa placed Hims & Hers Health into its Acquirer Monitoring Program after a billing dispute spike, adding penalty costs amid an FTC lawsuit and margin contraction.
